Evidence map›Paper›PMID 35342387›Full record

ReviewFrontiers in pharmacology2021

Overview of Cannabis including Kampo Medicine and Therapy for Treatment of Dementia: A Review.

Tibor Wenger, Kazuhito Watanabe, Yui Sasaki, Keiko Kanazawa, Koichi Shimizu, Supaart Sirikantaramas, Yoshinari Shoyama, Futoshi Taura, Satoshi Morimoto, Yukihiro Shoyama

Open access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Frontiers in pharmacology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.5field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 6 institutions in 3 countries.

Tibor WengerDepartment of Anatomy, Histology and Embryology, Semmelweis University, Budapest, Hungary.
Kazuhito WatanabeDaiichi University of Pharmacy, Fukuoka, Japan.
Yui SasakiAssociation for Health Economics Research and Social Insurance and Welfare, Tokyo, Japan.
Keiko KanazawaAssociation for Health Economics Research and Social Insurance and Welfare, Tokyo, Japan.
Koichi ShimizuAssociation for Health Economics Research and Social Insurance and Welfare, Tokyo, Japan.
Supaart SirikantaramasMolecular Crop Research Unit, Department of Biochemistry, Faculty of Science, Chulalongkorn University, Bangkok, Thailand.
Yoshinari ShoyamaBonac Corporation, BIO Factory, Fukuoka, Japan.
Futoshi TauraFaculty of Pharmacy and Pharmaceutical Science, Toyama, Japan.
Satoshi MorimotoFaculty of Pharmaceutical Science, Fukuoka, Japan.
Yukihiro ShoyamaFaculty of Pharmacy, Nagasaki International University, Nagasaki, Japan.
Nagasaki International University · JPInstitute for Health Economics and Policy · JPChulalongkorn University · THDaiichi University of Pharmacy · JPSemmelweis University · HUTohoku Medical and Pharmaceutical University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

anti-dementiacannabinoid biosynthetic enzymeCannabis sativaCB1 and CB2 receptorkampo medicine

Identifiers

PMID35342387
PMCPMC8942766
OpenAlexW4214520366

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.